Products
Uridine triacetate was approved in the United States in 2015 as an oral granule (Xuriden).
Structure and properties
Uridine triacetate (C15H18N2O9, Mr = 370.3 g/mol) is a triacetylated uridine. The prodrug is converted to uridine in the organism by ester hydrolysis.
Effects
Uridine triacetate replaces in the body the missing uridine, which is used for biosynthesis of uridine nucleotides. Uridine inhibits the overproduction of orotic acid and inhibits its excretion by the kidney. Uridine triacetate has a half-life of 2 to 2.5 hours.
Indications
For the treatment of hereditary orotaziduria.
Dosage
According to the SmPC. The drug is taken once daily with food.
Contraindications
Uridine triacetate is contraindicated in case of hypersensitivity. For complete precautions, see the drug label.
Interactions
Uridine triacetate is a substrate of P-glycoprotein. In contrast, it does not interact with CYP450 isoenzymes.
Adverse effects
Adverse effects are not known.
